房颤合并颅内出血史患者口服抗凝药的安全性与疗效:系统综述与荟萃分析
本系统综述与荟萃分析比较直接口服抗凝药(DOACs)与维生素K拮抗剂(VKAs)在房颤合并颅内出血史患者中的结局。共纳入5项观察性研究,结果显示DOACs与较低的复发性颅内出血、缺血性卒中及全因死亡风险相关。但证据确定性为中等至极低,结果应作为假设生成并用于共同决策。
要点
- 房颤合并颅内出血史患者使用DOACs较VKAs复发性颅内出血风险更低(HR 0.65)。
- 缺血性卒中和全因死亡的优势估计在更保守敏感性分析中失去统计学显著性。
- 证据确定性中等至极低,不应据此做出确定性实践改变。
核心结论
- DOACs在复发性颅内出血、缺血性卒中和全因死亡方面似乎优于VKAs,但证据确定性为中等至极低。
- 在获得随机证据前,这些发现应作为假设生成并用于共同决策,而非确定性实践改变。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus和ScienceDirect,时间截至2026年3月16日。
- 纳入5项观察性研究,偏倚风险评估采用ROBINS-I V.2工具,汇总效应量使用随机效应模型计算HR及95%CI。
主要发现
- 复发性颅内出血:5项研究,DOACs较VKAs的HR为0.65(95%CI 0.53至0.79)。
- 缺血性卒中:4项研究,DOACs较VKAs的HR为0.80(95%CI 0.68至0.94)。
- 全因死亡:3项研究,DOACs较VKAs的HR为0.64(95%CI 0.45至0.89)。
- 缺血性卒中和复发性颅内出血无异质性(I²=0%),但全因死亡异质性显著(I²=89%)。
- 复发性颅内出血结果在留一法、Hartung-Knapp-Sidik-Jonkman和重叠校正敏感性分析中保持稳健,而缺血性卒中和全因死亡估计在更保守方法下失去统计学显著性。
关键数值与推荐
- 复发性颅内出血:HR 0.65,95%CI 0.53至0.79。
- 缺血性卒中:HR 0.80,95%CI 0.68至0.94。
- 全因死亡:HR 0.64,95%CI 0.45至0.89。
- 全因死亡异质性I²=89%,缺血性卒中和复发性颅内出血I²=0%。
临床怎么用
- 对于房颤合并颅内出血史且需抗凝的患者,DOACs可能是较VKAs更安全的选择。
- 临床决策应结合患者个体风险,并采用共同决策方式,等待随机对照研究进一步验证。
局限性
- 仅纳入观察性研究,存在残余混杂和选择偏倚的可能。
- 全因死亡结局异质性显著,且在保守敏感性分析中统计学显著性不稳定。
- 证据确定性为中等至极低,结论不能作为确定性实践改变依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction The optimal anticoagulation strategy for patients with atrial fibrillation (AF) and prior intracranial haemorrhage (ICH) remains uncertain. Although direct oral anticoagulants (DOACs) have demonstrated a more favourable safety profile than vitamin K antagonists (VKAs) in the general AF population, comparative evidence in patients with previous ICH is limited. Methods We conducted a systematic review and meta-analysis comparing DOACs and VKAs in patients with AF and prior ICH. PubMed, Scopus and ScienceDirect were searched from inception to 16 March 2026. Outcomes of interest were ischaemic stroke, recurrent ICH and all-cause mortality. Risk of bias was assessed using Risk of Bias In Non-randomised Studies of Interventions (ROBINS-I) V.2. Pooled HRs with 95% CIs were calculated using random-effects models. Results Five observational studies were included. Compared with VKAs, DOACs were associated with a lower risk of recurrent ICH (5 studies, HR 0.65, 95% CI 0.53 to 0.79), ischaemic stroke (4 studies, HR 0.80, 95% CI 0.68 to 0.94) and all-cause mortality (3 studies, HR 0.64, 95% CI 0.45 to 0.89). Heterogeneity was absent for ischaemic stroke and recurrent ICH (I²=0%) but substantial for mortality (I²=89%). The recurrent ICH finding remained robust across leave-one-out, Hartung-Knapp-Sidik-Jonkman and overlap-adjusted sensitivity analyses, whereas the ischaemic stroke and mortality estimates lost statistical significance under more conservative methods. Conclusion DOACs appeared favourable over VKAs for recurrent ICH, ischaemic stroke and mortality, but certainty of evidence ranged from moderate to very low. These findings are hypothesis-generating and should inform shared decision-making, not definitive practice change, pending randomised evidence. PROSPERO registration number CRD420261333839.
引用
- Open Heart:Walking a tightrope: the safety and efficacy of oral anticoagulants in atrial fibrillation patients with prior intracranial haemorrhage: a systematic review and meta-analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。